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Background. Conventional management of thyrotoxicosis includes antithyroid drugs, radioactive iodine, and surgery while
adjunctive treatment includes beta-blockers, corticosteroids, inorganic iodide and iopanoic acid. Very rarely, patients may be
resistant to these modalities and require additional management. Case Presentation. A 50-year-old lady presented with weight
loss and palpitations diagnosed as atrial fibrillation. Her past history was significant for right thyroid lobectomy for thyrotoxicosis.
Thyroid functions tests at this presentation showed free T4 of 6.63 ng/dl (normal range: 0.93–1.7) and TSH of <0.005 µIU/mL
(normal range: 0.4–4.0). She was given aspirin, propranolol, heparin and carbimazole; however free T4 failed to normalize.
Switching to propylthiouracil (PTU) did not prove successful. She was then given high doses of prednisolone (1mg/kg/day) and
lithium (400mg twice daily) which prepared the patient for radioactive iodine treatment by reducing free T4 levels (2.82 ng/dl).
Two doses of radioactive iodine were then administered 6 months apart. Subsequently she became hypothyroid and was started
on thyroid replacement therapy. Conclusion. This case highlights management options in patients with resistant thyrotoxicosis.
Radioactive iodine and surgery are definitive modes of treatment in such complex cases while steroids and lithium play an
important role in preparing patients for more definitive treatment.
1. Background
Thyrotoxicosis aﬀects approximately 2% of women and 0.2%
of men [1]. Graves disease is the most common cause of thy-
rotoxicosis. It is an autoimmune disorder characterized by a
constellation of clinical features including hyperthyroidism,
diﬀuse goitre, ophthalmopathy, and dermopathy [2].
Conventional principal management of thyrotoxicosis
includes antithyroid drugs, radioactive iodine, and surgery.
Adjunctive treatment in the form of beta-blockers, corti-
costeroids, inorganic iodide, and iopanoic acid may also be
used for more prompt control of symptoms [3–6]. However,
a few cases may require additional treatment despite these
conventional modalities to achieve euthyroid state.
We have described a case of thyrotoxicosis in a patient
with Graves disease that was resistant to antithyroid drugs.
High-dose steroids and lithium were additionally adminis-
tered to improve her thyrotoxicosis so that radioactive iodine
could be administered later.
2. Case Presentation
A 50-year-old lady from Afghanistan presented to our insti-
tution with complaints of undocumented weight loss, pal-
pitations, and anxiety for the past 4 weeks. Her past history
was significant for right thyroid lobectomy for thyrotoxicosis
more than four years ago. She did not have any history of a
recent iodine load. Clinically, she had an irregularly irregular
pulse of 110–120 beats per minute. Physical examination
showed signs of thyrotoxicosis, a diﬀusely enlarged left thy-
roid lobe and thyroid bruit. Her electrocardiograph (ECG)
showed atrial fibrillation with rapid ventricular rate (RVR).
Thyroid functions tests were ordered which showed severe
thyrotoxicosis with free T4 of 6.63 ng/dl (normal range: 0.93–
1.7) and TSH of <0.005 µIU/mL (normal range: 0.4–4.0). A
diagnosis of Graves disease was made on the basis of high
titres of thyroid antibodies (antithyroid peroxidase antibody
>1000 IU/mL (normal range: 0–12)). In addition, the pres-
ence of a thyroid bruit is also considered pathognomonic for
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Graves disease. The patient did not have any signs of Graves
ophthalmopathy or dermopathy.
Echocardiography showed moderately dilated right atri-
um with a severely dilated left atrium and moderate to severe
mitral regurgitation and no evidence of a thrombus. Her left
ventricular systolic function was moderately reduced with
estimated ejection fraction of 35–40%. Ultrasound of the
neck showed heterogeneously enlarged left lobe of thyroid
gland which measured 4 × 3.5 cm; no discrete nodules were
identified.
It was planned that the patient be made euthyroid with
free T4 values as near normal as possible, so that radioactive
iodine (RAI) could be safely administered without the risk
of precipitating thyrotoxic crises. The patient was started on
aspirin, propranolol, heparin, and carbimazole. Her initial
dose of carbimazole was 30mg/day but was increased up to
90mg/day due to no improvement in symptoms. Her free T4
failed to normalize despite maximum doses of carbimazole.
Switching to propylthiouracil (PTU) and administering
maximum doses had minimal benefit with free T4 values
still bordering on 4 ng/dl. The patient was an illiterate lady
who was accompanied by her son at every visit. The issue
of compliance was thoroughly ascertained through direct
questioning and visual inspection of pill bottles at the initial
visit and then at every subsequent visit thereafter. The patient
appeared to be compliant in taking her medications.
She was then given high doses of prednisolone (1mg/kg/
day) along with lithium (400mg twice daily) to make her
euthyroid so that RAI could be safely given in the future. The
patient showed a good response to these treatment modali-
ties, and her free T4 further reduced to 2.82 ng/dl. However,
despite intensive medical management, her thyrotoxic symp-
toms showed little improvement overall.
PTUwas stopped 5 days before giving the RAI to enhance
its uptake by the thyroid. After a period of 12 weeks from
the initial presentation to our institution, the patient was
administered 15mCi of RAI. Unfortunately, measurement of
radioactive iodine uptake prior to the administration of RAI
is not performed at our institution.
She was then given potassium iodide for the next two
weeks. Ross et al. [7] have shown that adjunctive potassium
iodide given after RAI has the potential to treat thyrotoxicosis
more rapidly than RAI alone without any adverse eﬀect on
outcomes at 1 year. Although not standard practice yet, this
particular method of treatment [7] has been utilized by at
least 19 authors in the management of patients with thyro-
toxicosis. As our patient was resistant to antithyroid drugs,
we explored all available options including administration of
potassium iodide for a short duration of time.
The patient remained stable without the occurrence of
thyrotoxic crises. After 3 days, PTU was restarted at a dose of
1200mg/day. Her free T4 measured at three months after the
RAI was 2.93 ng/dl. After 6 months of initial administration
of RAI, the patient was still thyrotoxic. A second dose of
20mCi of RAI was then administered.
Three weeks after receiving the second RAI dose, her free
T4 decreased to 1.81 ng/dl. Another repeat measurement in
three weeks showed a free T4 value of 0.87 ng/dl. The patient
was started on thyroid replacement therapy (at 50mcg/day)
soon thereafter as she had become hypothyroid. Her clinical
condition has remained stable at 6 months followup.
3. Discussion
3.1. Causes of Thyrotoxicosis. Graves disease is the most com-
mon cause of thyrotoxicosis. Thyrotoxicosis can also be
associated with other entities such as toxic nodular goiter,
human chorionic gonadotropin, pituitary resistance to thy-
roid hormone regulation, TSH-secreting pituitary adenoma,
subacute thyroiditis, ectopic hormone production, or exog-
enous ingestion of thyroid hormone. In addition, it can also
be iodine induced [5] or may occur with postpartum thy-
roiditis.
3.2. Medical Management of Thyrotoxicosis
3.2.1. Thionamides. Methimazole/carbimazole are the main-
stay of treatment in the majority of patients with Graves-
associated thyrotoxicosis. PTU, on the other hand, is con-
sidered a second-line agent (except in the first trimester of
pregnancy) due to reports of associated severe hepatotoxicity.
These drugs decrease thyroid hormone synthesis, and control
of hyperthyroidism is usually achieved within several weeks.
Large doses of PTU have been reported to decrease the
peripheral conversion of T4 to T3 [3]. Thionamides also
have an important role in the long-term management of
patients with Graves disease. A treatment regime of 12–18
months has been reported to induce remission in 40–60%
of patients [8]. Although initially championed with a vogue
of enthusiasm, it has now been reported that block-replace
regimen (combined thionamide and thyroxine therapy) does
not increase the chances of long-term remission in patients
[6]. Common side eﬀects of thionamides include fever, urti-
caria, arthralgias, and mild elevations in transaminase levels
while more severe side eﬀects such as agranulocytosis, acute
inflammatory hepatitis, and vasculitis are rare [3].
3.2.2. Adjunctive Drugs. In certain instances, adjunctive
drugs may also be required to alleviate severe symptoms or
achieve euthyroidism more promptly. Such aggressive man-
agement is usually needed in elderly patients as well as pa-
tients with thyrotoxic heart disease. Beta-blockers, high-
dose glucocorticoids, and iopanoic acid (an oral cholecysto-
graphic agent) all inhibit the peripheral conversion of T4 to
T3 while inorganic iodide and iopanoic acid decrease synthe-
sis and release of thyroid hormone [3]. Sodium ipodate has
been used for the long-term control of Graves thyrotoxicosis
and is believed to cause a more rapid fall in thyroid hormone
level and provide an easier control of symptoms. However, it
may itself rarely cause severe resistant hyperthyroidism when
used in the treatment of Graves disease [9].
3.3. Radioactive Iodine Ablation. 131I is an eﬀective definitive
treatment option for Graves thyrotoxicosis; a single dose is
successful in achievement of euthyroid status in the majority
of patients within 8 weeks [10]. However, 131I causes per-
manent hypothyroidism in almost all patients in the long
run [3, 6]. Other adverse aspects associated with the use of
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131I also merit consideration; these include initial worsening
of thyrotoxicosis and development or worsening of Graves
ophthalmopathy [3]. In our patient, the first dose of RAI
was not successful in controlling the hyperthyroid symptoms
even after 6 months. Therefore, a second dose of RAI was
administered. An expected side eﬀect of this therapy oc-
curred in our patient in the form of hypothyroidism. The
patient was then put on thyroid replacement therapy.
3.4. Surgical Management of Thyrotoxicosis. Thyroidectomy
is the definitive surgical management for Graves thyrotoxico-
sis and usually requires a short course of pretreatment with
thionamides or inorganic iodine to achieve euthyroid state;
this reduces operative complications and thyroid vascular-
ity. Although subtotal thyroidectomy was once practiced,
most surgeons now recommend complete thyroidectomy to
minimize chances of relapse [3, 6]. The present case also
demonstrates why subtotal thyroidectomy in this setting has
fallen out of favor. While the procedure is not associated with
worsening of Graves ophthalmopathy, it can be complicated
by bleeding, infection, recurrent laryngeal nerve injury, hy-
pocalcemia, and permanent hypothyroidism [3].
The modus operandi selected for each patient should
be individualized on a case-per-case basis. A consideration
should be given to the merits and demerits of the chosen
modality. Local and regional trends may also influence this
decision. For example, radioiodine is the preferred primary
modality in the USA while antithyroid drug therapy is pre-
ferred in Europe and Australia [6].
3.5. Resistant Thyrotoxicosis. Majority of the patients re-
spond to the conventional treatments outlined above. How-
ever, literature review showed sporadic reports of patients
with resistant thyrotoxicosis.
3.5.1. Etiologies of Resistant Thyrotoxicosis. Etiologies of re-
sistant thyrotoxicosis in literature include type I amiodarone-
induced thyrotoxicosis (AIT) [11] and Graves disease [12–
16]. Refractory cases have mostly shown resistance to high-
dose thionamides and beta-blockers; rarely resistance to io-
dine has also been reported [11–13, 15–18]. In our patient,
resistance to two diﬀerent thionamides was seen. Also, beta-
blockers did not improve the thyrotoxic symptoms.
3.5.2. Mechanisms of Resistance. Possible mechanisms medi-
ating resistance in cases refractory to conventional treatment
may range from drug malabsorption, rapid drug metabo-
lism, antidrug antibodies, impairment of intrathyroidal drug
accumulation or action, and predominant elevation of T3
rather than T4 levels [15].
3.5.3. Workup of Patients with Resistant Thyrotoxicosis. Eval-
uation of resistant cases should always start with the evalu-
ation of patient compliance [17]. We were attentive to this
aspect in the management of our patient and found her to
be compliant in taking her medications. This compliance
was ascertained through direct questioning at the initial visit
and then at every subsequent visit thereafter. Malabsorption
should also be ruled out in these patients through careful
history taking and physical examination. In our patient, there
was nothing remarkable in the history or physical exam-
ination to suggest malabsorption as a potential cause for
drug resistance. The measurement of drug levels or anti-drug
antibodies may then be undertaken. However, these tests are
usually not available for routine clinical use; we also did
not perform them at our institution due to nonavailability.
Alternatively, resistance to drugs can be tested by performing
a perchlorate discharge test four hours after drug intake
under medical supervision. However, it should be noted that
pharmaceutical-grade perchlorate may not be universally
available. For example, it is no longer manufactured in the
USA. Although not performed in our patient, iodine mea-
surement of urinary iodine excretion may be additionally
undertaken to evaluate iodine contamination [19].
3.5.4. Management of Resistant Thyrotoxicosis. Diﬀerent ap-
proaches have been used for the management of resistant
thyrotoxicosis. Such patients can either be oﬀered surgery or
radioactive iodine ablation as the definitive treatment. How-
ever, achievement of a euthyroid state before opting for any
of these interventions is recommended in order to minimize
potential complications such as precipitation of thyroid crisis
[13, 14, 17]. Some authors have advocated the use of iopanoic
acid prior to definitive thyroidectomy in patients with drug-
resistant Type I AIT. [11] as well as in patients with Graves
disease [12]. However, iopanoic acid, like perchlorate, is no
longer universally available and is no longer manufactured,
for example, in the USA. Although corticosteroids have tradi-
tionally been used in the management of thyroid crisis [20],
some authors have also reported their use in themanagement
of resistant thyrotoxicosis. Dexamethasone, in conjunction
with iopanoic acid, has been used for the rapid preoperative
preparation of uncontrolled, resistant thyrotoxicosis [12].
Similarly, prednisolone (20mg/day), added to antithyroid
drugs, has been successfully used to achieve euthyroid state in
patients with resistant thyrotoxicosis before administration
of radioiodine [17]. Cholestyramine, a bile acid sequestrant,
has been shown to cause a dramatic decline in serum thyroid
hormone levels in Graves associated thyrotoxicosis resistant
to conventional treatment [13].
Lithium, an agent used to treat bipolar aﬀective disorder,
has shown favorable response in resistant cases of thyrotox-
icosis. Lithium probably increases retention of radioactive
iodine in the thyroid in treatment-resistant Graves thyrotoxi-
cosis and has accordingly been used as an adjunct to radioac-
tive iodine in such cases [16, 21–24]. Such use is especially
beneficial in patients with underlying cardiovascular disor-
ders in whom even minor elevations of thyroid hormone
levels can prove seriously deleterious [24]. We successfully
used a combination of lithium and steroids to prepare the
patient for the RAI procedure.
4. Conclusion
This case highlights an important yet uncommon clinical
entity of resistant thyrotoxicosis. Our patient was resistant to
the conventional management including beta-blockers and
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thyrostatics. We have also discussed the possible manage-
ment options in such patients. Radioactive iodine or surgery
are the definitive modes of treatment in such complex cases
while steroids and lithium may play an important part in
preparing the patients formore definitive forms of treatment.
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